Peer-influenced content. Sources you trust. No registration required. This is HCN.
Conexiant
TECNIS PureSee IOL is the first and only US FDA‑approved extended depth of focus (EDOF) IOL with no warning on loss of contrast sensitivity
Ophthalmology March 24th 2026
Ophthalmology Advisor
The combined action of the drugs results in pupil constriction, resulting in a pinhole effect that improves near visual acuity and depth of focus in patients with presbyopia.
Ophthalmology March 9th 2026
The approval was supported by data from two phase 3 trials demonstrating improvement in near vision within 30 minutes after administration lasting up to 10 hours.
Family Medicine/General Practice November 10th 2025
Contact Lens Spectrum
Learn how an integrative approach involving specialty lenses and pharmaceuticals can revolutionize treatment strategies for ocular and corneal conditions.
Optometry September 26th 2023
Modern Optometry
New pharmaceutical interventions are significantly broadening the scope of presbyopia treatment. Discover how these emerging options can enhance your practice and improve patient care.
DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS